A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer

Badzio, A.; Kurowski, Krzysztof; Karnicka-Młodkowska, H; Jassem, Jacek

doi:10.1016/j.ejcts.2004.04.012

Cited by 93 publications

(43 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A matched-pair analysis comparing 67 patients who underwent surgery followed by adjuvant ChT and 67 patients who received conventional non-surgical management revealed a 5-year OS rate of 27% for the surgical group and 4% for the matched non-surgical cohort. Subset analysis confirmed significantly longer survival following surgery for T1-2 and N0-1 categories (Badzio et al 2004). Several trials have demonstrated that surgery with adjuvant ChT results in a favourable survival rate for stage I-III disease (Table 3; Brock et al 2005;Tsuchiya et al 2005;Antonio et al 2006;Bischof et al 2007;Lim et al 2008;Hanagiri et al 2009;Schreiber et al 2010;Yu et al 2010).…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute

Zhu

Zhou

Xue

et al. 2013

Eur J Cancer Care (Engl)

View full text Add to dashboard Cite

We evaluated the role of surgery followed by either chemotherapy (ChT) alone or chemotherapy and thoracic radiotherapy (ChT/TRT) versus sequential ChT/TRT in patients with clinical stage I or stage II small cell lung cancer (SCLC). Ninety-six patients received surgery (complete resection) followed by either ChT alone or ChT/TRT (Group I), while 49 patients were treated exclusively with sequential ChT/TRT (Group II). The ChT regimens consisted of either carboplatin/etoposide or cisplatin/etoposide. The total TRT dose was 50-60 Gy. For the whole group (n = 145), the median survival time was 54 months, and the 5-year overall survival (OS) rate was 48%. The corresponding figures for Group I were 91 months and 57%, respectively, and for Group II, they were 34.6 months and 31.4% respectively (P = 0.004). Multivariate analysis revealed that a Karnofsky Performance Status score ≥ 80 [hazard ratio (HR), 0.281; P = 0.015] and the treatment modality including surgery (HR, 0.503; P = 0.004) were independent favourable prognostic factors for OS.

show abstract

Section: Discussionmentioning

confidence: 86%

“…Subset analysis confirmed significantly longer survival following surgery for T1–2 and N0–1 categories (Badzio et al . ). Several trials have demonstrated that surgery with adjuvant ChT results in a favourable survival rate for stage I–III disease (Table ; Brock et al .…”

Section: Discussionmentioning

confidence: 97%

Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute

Zhu

Zhou

Xue

et al. 2013

Eur J Cancer Care (Engl)

View full text Add to dashboard Cite

show abstract

“…Since adequate primary tumor specimens of SCLC are difficult to obtain and typically small, we used previously described primary tumor specimens collected over a 20 year period from series of LD patients who underwent pulmonary resection (4). …”

Section: Introductionmentioning

confidence: 99%

Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer

Badzio

Wynes

Dziadziuszko

et al. 2010

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Purpose Identification of new therapies in small cell lung cancer (SCLC) is urgently needed. IGF1R is a tyrosine kinase receptor implicated in the pathogenesis of several malignancies and is potentially an attractive target for anti-cancer treatment. Knowledge about IGF1R protein expression, gene copy number and the prognostic relevance of these features in SCLC is limited. Methods We analyzed IGF1R protein expression and gene copy number in primary tumors from 90 SCLC patients (67 males and 23 females) who underwent pulmonary resection. IGF1R expression assessed by immunohistochemistry (IHC) with H-scores from 0 to 400 was evaluable in 84 patients, and IGF1R gene copy number assessed by silver in-situ hybridization (SISH) technique in 81 patients. Results Median H-score for IGF1R protein expression was 88 (range 0-400) and the proportion of positive immunostaining using cut-off H-score of 10 was 74%. Increased IGF1R gene copy number (an average of 4 or more copies per cell) was found in 15 cases (18.5%), 5 of whom (6.2%) showed gene amplification. There was a significant correlation between protein expression and gene copy number (r=0.49, p<0.005). IGF1R expression and gene copy number did not associate with clinicopathological factors such as patient age, tumor size, lymph node involvement, stage and survival. Conclusions SCLC is characterized by frequent high IGF1R protein expression, increased gene copy number and occasional occurrence of true gene amplification. These features may have important implications for future anti-IGF1R therapeutic approaches.

show abstract

“…Several small series have reported favorable survival outcomes in patients who underwent surgical resection . There are some recently published studies demonstrating that a high local control rate can be achieved in early stage SCLC patients (stage I‐IIIA), and this might, subsequently, result in favourable long‐term results .…”

Section: Discussionmentioning

confidence: 99%

Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer

Zhang

Chen

et al. 2014

Thoracic Cancer

View full text Add to dashboard Cite

Background: The role of surgery in limited small cell lung cancer (SCLC) is still controversial. To assess the role of surgery in SCLC we performed a retrospective analysis of survival in a group of limited stage patients, who were managed with trimodal therapy including surgery, or with chemotherapy and radiotherapy. Methods: We performed a retrospective survival analysis in a series of 153 limited stage SCLC patients treated between 1995 and 2013. Kaplan-Meier survival analysis and Cox regression analysis were used to calculate the overall survival of the surgical and non-surgical groups. Results: Median survival in all patients was 21.5 months. Median survival for surgical and non-surgical patients was 30.5 months and 16.9 months, respectively. The survival curves for the two arms are significantly different (P < 0.01). In multivariate analysis, the benefit of surgical treatment and thoracic radiotherapy varied in a timedependent fashion. Conclusions: Our results suggest that surgery added to chemotherapy and radiotherapy may be associated with a therapeutic benefit in limited SCLC.

show abstract

A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer

Abstract: Our results suggest a possible role of surgery in limited-stage SCLC. Thus, a randomised study addressing this issue seems to be justified.

Cited by 93 publications

References 21 publications

Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute

Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute

Increased Insulin-Like Growth Factor 1 Receptor Protein Expression and Gene Copy Number in Small Cell Lung Cancer

Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer

Contact Info

Product

Resources

About